Format

Send to

Choose Destination
Future Oncol. 2017 Mar;13(7):615-624. doi: 10.2217/fon-2016-0434. Epub 2016 Nov 2.

Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.

Author information

1
Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain.
2
Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
3
Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
4
Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
5
Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain.
6
Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
7
Department of Medical Oncology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
8
Endocrinology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
9
Department of Medical Oncology, Hospital Clínico Virgen de la Victoria y Regional de Málaga, Málaga, Spain.
10
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
11
Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
12
Department of Medical Oncology, Hospital Universitario de León, León, Spain.
13
Department of Medical Oncology, University of Manchester, Manchester, UK.

Abstract

BACKGROUND & METHODS:

Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs).

RESULTS:

Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%).

CONCLUSION:

This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.

KEYWORDS:

capecitabine; carcinoids; neuroendocrine tumors; pancreatic neuroendocrine tumors; retrospective study; temozolomide

PMID:
27802780
DOI:
10.2217/fon-2016-0434
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center